| 2025年中报 | 2024年年报 | 2024年中报 | 2023年年报 | |
|---|---|---|---|---|
| 营业收入(元) | ||||
| 口服制剂(元) | 19,842,658.92 | 61,037,725.56 | 33,576,843.78 | 60,866,846.83 |
| 原料药(元) | 2,197,714.77 | 8,797,641.28 | 5,577,599.77 | 11,542,395.14 |
| 注射剂(元) | 93,288,450.99 | 156,418,992.12 | 68,730,734.04 | 192,832,691.84 |
| 营业成本(元) | ||||
| 口服制剂(元) | 7,602,312.20 | 17,754,780.73 | 7,913,762.33 | 12,828,187.11 |
| 原料药(元) | 1,327,032.92 | 5,045,257.61 | 2,364,473.01 | 8,682,310.55 |
| 注射剂(元) | 42,759,138.13 | 75,634,087.71 | 25,122,552.70 | 56,115,219.74 |
| 毛利(元) | ||||
| 口服制剂(元) | 12,240,346.72 | 43,282,944.83 | 25,663,081.45 | 48,038,659.72 |
| 原料药(元) | 870,681.85 | 3,752,383.67 | 3,213,126.76 | 2,860,084.59 |
| 注射剂(元) | 50,529,312.86 | 80,784,904.41 | 43,608,181.34 | 136,717,472.10 |
| 毛利率(%) | ||||
| 口服制剂(%) | 61.69 | 70.91 | 76.43 | 78.92 |
| 原料药(%) | 39.62 | 42.65 | 57.61 | 24.78 |
| 注射剂(%) | 54.16 | 51.65 | 63.45 | 70.90 |
| 收入构成(%) | ||||
| 口服制剂(%) | 17.21 | 26.98 | 31.12 | 22.95 |
| 原料药(%) | 1.91 | 3.89 | 5.17 | 4.35 |
| 注射剂(%) | 80.89 | 69.13 | 63.71 | 72.70 |
| 毛利构成(%) | ||||
| 口服制剂(%) | 19.23 | 33.86 | 35.40 | 25.60 |
| 原料药(%) | 1.37 | 2.94 | 4.43 | 1.52 |
| 注射剂(%) | 79.40 | 63.20 | 60.16 | 72.87 |